Diagnostics de la rage Marché 2022 - Taille, croissance, tendances D'ici 2030

Marché des diagnostics de la rage (Analyse de la taille, de la part et des tendances, par type d'essai (essai d'anticorps fluorescents, test immunohistochimique, méthodes d'amplification, examen histologique, tests sérologiques, test d'inoculation de souris), par technologie (ELISA, PCR, techniques de chromatographie, etc.), par utilisation finale (hôpitals, centres de diagnostic, cliniques de soins palliatifs contre le cancer, etc.) Par région, période de prévision 2022 - 2030.

ID du rapport : RI_673923 | Dernière mise à jour : November 2024 | Format : ms word ms Excel PPT PDF

Ce rapport comprend les chiffres, statistiques et données du marché les plus récents
Table of Content

1.Introduction

1.1.Market Introduction
1.2.Market Research Methodology
1.2.1.Research Process
1.2.2.Primary Research
1.2.3.Secondary Research
1.2.4.Data Collection Technique
1.2.5.Data Sources
1.3.Market Estimation Methodology
1.3.1.Limitations of the Study
1.4.Product Picture of rabies diagnostic
1.5.Rabies Diagnostics Market: Classification
1.6.Geographic Scope
1.7.Years Considered for the Study
1.8.Research Methodology in Brief
1.9.Parent Market Overview
1.10. Rabies Diagnostic Market Regional Demand
1.11. Research Programs/Design
1.12. Market Breakdown and Data Triangulation Approach
1.13. Data Source
1.14. Secondary Sources
1.15. Primary Sources
1.16. Primary Interviews
1.17. Average Primary Breakdown Ratio

2.Market Dynamics

2.1.Drivers
2.1.1.Drivers
2.2.Restraints
2.2.1.Restraints
2.3.Opportunity
2.3.1.Impact Forces on Market Dynamics
2.3.2.Impact Forces During the Forecast Years
2.4.Industry Value Chain
2.4.1.Upstream Analysis
2.4.2.Downstream Analysis
2.4.3.Distribution Channel
2.4.4.Direct Channel
2.4.5.Indirect Channel
2.5.Potential Customers
2.6.Manufacturing/Operational Cost Analysis
2.7.Pricing Analysis by Region
2.8.Key Technology Landscape
2.9.Porter\'s Analysis
2.9.1.Supplier Power
2.9.2.Buyer Power
2.9.3.Substitution Threat
2.9.4.Threat from New Entry
2.9.5.Competitive Rivalry
2.10. PESTEL Analysis
2.10.1. Political Factors
2.10.2. Economic Factors
2.10.3. Social Factors
2.10.4. Technological Factors
2.10.5. Environmental Factors
2.10.6. Legal Factors

3.Rabies Diagnostics Market Segmentation, by Revenue (USD Million), (2023-2030)

3.1.By Test Type
3.1.1.Fluorescent Antibody Test (FAT)
3.1.2.Immunohistochemical Test
3.1.3.Amplification Methods
3.1.4.Histologic Examination
3.1.5.Serology Tests
3.1.6.Mouse Inoculation Test
3.2.By Technology
3.2.1.ELISA
3.2.2.PCR
3.2.3.Chromatography Techniques
3.2.4.Others
3.3.By End User
3.3.1.Hospitals
3.3.2.Diagnostic centers
3.3.3.Cancer Palliative care clinics
3.3.4.Others

4.Rabies Diagnostics Market Overview, By Region

4.1. North America Rabies Diagnostics Market Revenue (USD Million), by Countries, (2023-2030)
4.1.1. U.S.
4.1.1.1.By Test Type
4.1.1.2.By Technology
4.1.1.3.By End User
4.1.2.Canada
4.1.3.Mexico
4.2.Rabies Diagnostics Market Revenue (USD Million), by Countries, (2023-2030)
4.2.1.Germany
4.2.2.France
4.2.3.UK
4.2.4.Spain
4.2.5.Russia
4.2.6.Italy
4.2.7.BENELUX
4.3.Asia Pacific Rabies Diagnostics Market Revenue (USD Million), by Countries, (2023-2030)
4.3.1. China
4.3.2. Japan
4.3.3. Australia
4.3.4. South Korea
4.3.5. India
4.3.6. ASEAN
4.4.Latin America Rabies Diagnostics Market Revenue (USD Million), by Countries, (2023-2030)
4.4.1. Brazil
4.4.2. Argentina
4.4.3. Chile
4.5.Middle East and Africa Rabies Diagnostics Market Revenue (USD Million), by Countries, (2023-2030)
4.5.1.GCC
4.5.2.Turkey
4.5.3.South Africa

5.Rabies Diagnostics Market Revenue: Competitive Analysis, 2022

5.1.Key Strategies by Players
5.2.Revenue (USD Million) and Market Share (%), By Manufacturers, 2022
5.3.Player Positioning by Market Players, 2022

6.Competitive Analysis

6.1.Bio-Rad Laboratories
6.1.1.Business Overview
6.1.2.Business Financials (USD Million)
6.1.3.Product Category, Type, and Specification
6.1.4.Main Business/Business Overview
6.1.5.Geographical Analysis
6.1.6.Recent Development
6.1.7.SWOT Analysis
6.2.Merck KGaA
6.3.Aviva Systems Biology
6.4.Creative Diagnostics
6.5.MyBioSource
6.6.Abbexa Ltd
6.7. Norgen Biotek
6.8.EXPRESS BIOTECH INTERNATIONAL, INC

7.Market Research Findings & Conclusion

Disclaimer
Sélectionner la licence
Utilisateur unique : $3860   
Multi-utilisateur : $5460   
Utilisateur professionnel : $7460   
Acheter maintenant

SSL sécurisé crypté

Reports Insights
Why Choose Us
Guaranteed Success

Guaranteed Success

We gather and analyze industry information to generate reports enriched with market data and consumer research that leads you to success.

Gain Instant Access

Gain Instant Access

Without further ado, choose us and get instant access to crucial information to help you make the right decisions.

Best Estimation

Best Estimation

We provide accurate research data with comparatively best prices in the market.

Discover Opportunitiess

Discover Opportunities

With our solutions, you can discover the opportunities and challenges that will come your way in your market domain.

Best Service Assured

Best Service Assured

Buy reports from our executives that best suits your need and helps you stay ahead of the competition.

Témoignages de clients

Reports Insights have understood our exact need and Delivered a solution for our requirements. Our experience with them has been fantastic.

MITSUI KINZOKU, Project Manager

I am completely satisfied with the information given in the report. Report Insights is a value driven company just like us.

Privacy requested, Managing Director

Report of Reports Insight has given us the ability to compete with our competitors, every dollar we spend with Reports Insights is worth every penny Reports Insights have given us a robust solution.

Privacy requested, Development Manager

Sélectionner la licence
Utilisateur unique : $3860   
Multi-utilisateur : $5460   
Utilisateur professionnel : $7460   
Acheter maintenant

SSL sécurisé crypté

Reports Insights
abbott Mitsubishi Corporation Pilot Chemical Company Sunstar Global H Sulphur Louis Vuitton Brother Industries Airboss Defence Group UBS Securities Panasonic Corporation